Study: NCT00598169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Part A: Velcade Day 1 and Day 8 of a 28-day cycle, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2 Part B: Velcade on Days 1 and 8 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Part A: Velcade Day 1 and Day 8 of a 28-day cycle, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2 Part B: Velcade on Days 1 and 8 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be dosed to an AUC=5, calculated using the Calvert formula (5 x \[creatinine clearance + 25\]; the maximum dose of carboplatin is 750 mg.~Part A: AUC=5 (maximum 750 mg) IV administered on Day 9. Part B: AUC=5 (maximum 750 mg) IV administered on Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be dosed to an AUC=5, calculated using the Calvert formula (5 x \[creatinine clearance + 25\]; the maximum dose of carboplatin is 750 mg.~Part A: AUC=5 (maximum 750 mg) IV administered on Day 9. Part B: AUC=5 (maximum 750 mg) IV administered on Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Part A: 20 mg IV on Days 8-10. Part B: 20 mg IV on Days 1-3 and on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Part A: 20 mg IV on Days 8-10. Part B: 20 mg IV on Days 1-3 and on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Part A: 100 mg/m2 IV Days 8-10. Part B: 100 mg/m2 IV daily on Days 1 to 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Part A: 100 mg/m2 IV Days 8-10. Part B: 100 mg/m2 IV daily on Days 1 to 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Part A: 5000 mg/m2 mixed with an equal amount of Mesna as a 24 hour continuous IV infusion on Day 9.~Part B: 5000 mg/m2 mixed with an equal dose of Mesna administered via continuous infusion for 24 hours beginning on Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Part A: 5000 mg/m2 mixed with an equal amount of Mesna as a 24 hour continuous IV infusion on Day 9.~Part B: 5000 mg/m2 mixed with an equal dose of Mesna administered via continuous infusion for 24 hours beginning on Day 2.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlate EBV/HHV-8 viral load changes with lymphoma response. HIV and EBV/HHV-8 viral loads will be assessed on baseline, day 2, 4, and 8 of week 1 of Part A.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlate EBV/HHV-8 viral load changes with lymphoma response. HIV and EBV/HHV-8 viral loads will be assessed on baseline, day 2, 4, and 8 of week 1 of Part A.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Peripheral blood mononuclear cells will be collected at Day 1 prior to chemotherapy, Day 2, 4 and 8 (prior to chemotherapy) then weekly during Part A, just prior to each additional cycle of Part B and at treatment completion. Western blot using antibody specific for APOBEC3G and antibody against actin for internal control will be used to quantify APOBEC3G levels. Changes at will be compared with baseline using a paired t-test.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Peripheral blood mononuclear cells will be collected at Day 1 prior to chemotherapy, Day 2, 4 and 8 (prior to chemotherapy) then weekly during Part A, just prior to each additional cycle of Part B and at treatment completion. Western blot using antibody specific for APOBEC3G and antibody against actin for internal control will be used to quantify APOBEC3G levels. Changes at will be compared with baseline using a paired t-test.